Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
BURLINGTON, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D)), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of Fractyl Health, will participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024, at 9:00 a.m. EDT.
To register in advance for the presentation webcast, sign up
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at .
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit .
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
, 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
, 978.760.5622
Investor Contact
Stephen Jasper, Gilmartin Group
, 619.949.3681
